Day One Biopharmaceuticals, Inc.
DAWN
$0.30
Change (1 day)
$18.07
Year High
$9.67
Year Low
Categories
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Day One Biopharmaceuticals, Inc. (DAWN) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -230,376,000 | 29.51 M | 376.05 M | 375.27 M | |
| 2022 | -84,449,000 | 17.02 M | 349.06 M | 347.87 M | |
| 2021 | -284,089,000 | 8.67 M | 289.82 M | 289.37 M | |
| 2020 | -43,326,000 | 94.16 M | 45.66 M | 45.07 M | |
| 2019 | -27,332,000 | 32.53 M | 27.34 M | 27.34 M |